Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eyenovia Inc | EYEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.5835 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.5835 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.501 - 5.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.5835 | USD |
Eyenovia Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 25.59M | 44.12M | - | 4k | -27.26M | -0.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eyenovia News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EYEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.54 | 0.5989 | 0.51 | 0.5495829 | 948,827 | 0.0435 | 8.06% |
| 1 Month | 1.01 | 1.02 | 0.501 | 0.6486374 | 1,375,384 | -0.4265 | -42.23% |
| 3 Months | 1.85 | 2.57 | 0.501 | 1.29 | 1,249,433 | -1.27 | -68.46% |
| 6 Months | 1.17 | 2.57 | 0.501 | 1.39 | 794,909 | -0.5865 | -50.13% |
| 1 Year | 4.85 | 5.85 | 0.501 | 1.89 | 595,077 | -4.27 | -87.97% |
| 3 Years | 5.30 | 6.63 | 0.501 | 2.50 | 342,494 | -4.72 | -88.99% |
| 5 Years | 6.79 | 7.72 | 0.501 | 3.19 | 304,959 | -6.21 | -91.41% |
Eyenovia Description
| Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
